Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets

被引：0
作者：
Cho, William C. S. [1 ]
Roukos, Dimitrios H. [2 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] GenNetMed Ioannina Univ, Ctr Biosyst & Genom Network Med CBS, Ioannina, Greece
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 01期
关键词：
breast cancer; drugs; genome; HER2-positive; trastuzumab; trastuzumab emtansine; NEXT-GENERATION; PHASE-II; ARCHITECTURE; LAPATINIB; PLUS;
D O I：
10.1586/ERA.12.152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 8
页数：4
相关论文
共 50 条
[41]   Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer [J].
Manso, Luis ;
Sanchez-Munoz, Alfonso ;
Calvo, Isabel ;
Izarzugaza, Yann ;
Plata, Jessica ;
Rodriguez, Cesar .
BREAST CARE, 2018, 13 (04) :277-283
[42]   The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases [J].
Dong, Rongrong ;
Ji, Jiali ;
Liu, Hong ;
He, Xuexin .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 :20-26
[43]   Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial [J].
Yan, Hongjing ;
Yu, Kewei ;
Zhang, Kaile ;
Liu, Linxia ;
Li, Yue .
ONCOTARGET, 2017, 8 (60) :102458-102467
[44]   First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer [J].
Araki, Kazuhiro ;
Fukada, Ippei ;
Yanagi, Hiroyo ;
Kobayashi, Kokoro ;
Shibayama, Tomoko ;
Horii, Rie ;
Takahashi, Shunji ;
Akiyama, Futoshi ;
Ohno, Shinji ;
Ito, Yoshinori .
BREAST, 2017, 35 :78-84
[45]   Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab [J].
Gradishar, W. J. .
ANNALS OF ONCOLOGY, 2013, 24 (10) :2492-2500
[46]   Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer [J].
Chang, Helena R. .
CANCER, 2010, 116 (12) :2856-2867
[47]   Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer [J].
Ferrario, C. ;
Wong, A. ;
Gao, T. ;
Bouganim, N. ;
Aloyz, R. ;
Panasci, L. C. .
JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) :32-35
[48]   Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer [J].
Andrew D. Seidman ;
Larry Norton .
Current Oncology Reports, 2005, 7 (1) :9-11
[49]   Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial [J].
Tolaney, Sara M. ;
Tayob, Nabihah ;
Dang, Chau ;
Yardley, Denise A. ;
Isakoff, Steven J. ;
Valero, Vicente ;
Faggen, Meredith ;
Mulvey, Therese ;
Bose, Ron ;
Hu, Jiani ;
Weckstein, Douglas ;
Wolff, Antonio C. ;
Reeder-Hayes, Katherine ;
Rugo, Hope S. ;
Ramaswamy, Bhuvaneswari ;
Zuckerman, Dan ;
Hart, Lowell ;
Gadi, Vijayakrishna K. ;
Constantine, Michael ;
Cheng, Kit ;
Briccetti, Frederick ;
Schneider, Bryan ;
Garrett, Audrey Merrill ;
Marcom, Kelly ;
Albain, Kathy ;
DeFusco, Patricia ;
Tung, Nadine ;
Ardman, Blair ;
Nanda, Rita ;
Jankowitz, Rachel C. ;
Rimawi, Mothaffar ;
Abramson, Vandana ;
Pohlmann, Paula R. ;
Van Poznak, Catherine ;
Forero-Torres, Andres ;
Liu, Minetta ;
Ruddy, Kathryn ;
Zheng, Yue ;
Rosenberg, Shoshana M. ;
Gelber, Richard D. ;
Trippa, Lorenzo ;
Barry, William ;
DeMeo, Michelle ;
Burstein, Harold ;
Partridge, Ann ;
Winer, Eric P. ;
Krop, Ian .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) :2375-+
[50]   Role of trastuzumab in the management of HER2-positive metastatic breast cancer [J].
Milani, Andrea ;
Montemurro, Filippo ;
Gioeni, Luisa ;
Aglietta, Massimo ;
Valabrega, Giorgio .
BREAST CANCER-TARGETS AND THERAPY, 2010, 2 :93-109
12345